Publicacións en colaboración con investigadores/as de Centre Hospitalier Universitaire de Liège (16)

2023

  1. A second update on mapping the human genetic architecture of COVID-19

    Nature

  2. The Dubai Definition and Diagnostic Criteria of Laryngopharyngeal Reflux: The IFOS Consensus

    Laryngoscope

2022

  1. Novel genes and sex differences in COVID-19 severity

    Human molecular genetics, Vol. 31, Núm. 22, pp. 3789-3806

2021

  1. Onset of effect and impact on health-related quality of life, exacerbation rate, lung function, and nasal polyposis symptoms for patients with severe eosinophilic asthma treated with benralizumab (ANDHI): a randomised, controlled, phase 3b trial

    The Lancet Respiratory Medicine, Vol. 9, Núm. 3, pp. 260-274

2020

  1. A Qualitative Research for Defining Meaningful Attributes for the Treatment of Inflammatory Bowel Disease from the Patient Perspective

    Patient, Vol. 13, Núm. 3, pp. 317-325

2019

  1. Development of scores assessing the refluxogenic potential of diet of patients with laryngopharyngeal reflux

    European Archives of Oto-Rhino-Laryngology, Vol. 276, Núm. 12, pp. 3389-3404

  2. Evaluation and Management of Laryngopharyngeal Reflux Disease: State of the Art Review

    Otolaryngology - Head and Neck Surgery (United States), Vol. 160, Núm. 5, pp. 762-782

  3. Molecular taxonomy of osteoarthritis for patient stratification, disease management and drug development: Biochemical markers associated with emerging clinical phenotypes and molecular endotypes

    Current Opinion in Rheumatology, Vol. 31, Núm. 1, pp. 80-89

2017

  1. Randomized comparison of liposomal amphotericin B versus placebo to prevent invasive mycoses in acute lymphoblastic leukaemia

    Journal of Antimicrobial Chemotherapy, Vol. 72, Núm. 8, pp. 2359-2367

  2. Soluble biochemical markers of osteoarthritis: Are we close to using them in clinical practice?

    Best Practice and Research: Clinical Rheumatology, Vol. 31, Núm. 5, pp. 705-720

2015

  1. Characterization of human disease phenotypes associated with mutations in TREX1, RNASEH2A, RNASEH2B, RNASEH2C, SAMHD1, ADAR, and IFIH1

    American Journal of Medical Genetics, Part A, Vol. 167, Núm. 2, pp. 296-312

2014

  1. Multinational evidence-based recommendations for the diagnosis and management of gout: Integrating systematic literature review and expert opinion of a broad panel of rheumatologists in the 3e initiative

    Annals of the Rheumatic Diseases, Vol. 73, Núm. 2, pp. 328-335

  2. The efficacy and safety of treatments for acute gout: Results from a series of systematic literature reviews including cochrane reviews on intraarticular glucocorticoids, colchicine, nonsteroidal antiinflammatory drugs, and interleukin-1 inhibitors

    Journal of Rheumatology, Vol. 41, Núm. SUPPL. 92, pp. 15-25

2012

  1. Enhanced interpretation of newborn screening results without analyte cutoff values

    Genetics in Medicine, Vol. 14, Núm. 7, pp. 648-655

2011

  1. Clinical validation of cutoff target ranges in newborn screening of metabolic disorders by tandem mass spectrometry: A worldwide collaborative project

    Genetics in Medicine, Vol. 13, Núm. 3, pp. 230-254

2006

  1. Meta- and pooled analysis of GSTT1 and lung cancer: A HuGE-GSEC review

    American Journal of Epidemiology, Vol. 164, Núm. 11, pp. 1027-1042